PIH29 RETROSPECTIVE EVALUATION OF THE IMPACT OF COST-SHARE INCREASES FOR SPECIALTY MEDICATIONS ON ADHERENCE AND PERSISTENCE  by Kim, YA et al.
A380 13th Euro Abstracts
respondents (of 53,524 total) using 1–2 (n = 6,434), 3–4 (5,529), or 5+ (5,727) pre-
scription medications for symptomatic conditions. Adherence was higher among those 
who saw a GP in the past 6 months (M = 1.19, SD = 1.24, n = 14,802) vs. those who 
did not (M = 1.36, SD = 1.29, n = 2,888), P < 0.001, and higher among those with 
a higher number of prescriptions (for 5+, 3–4, and 1–2: Ms = 0.99, 1.26, and 1.38; 
SDs = 1.18, 1.26, and 1.27, respectively), P < 0.001. Hospitalizations were lower 
among GP visitors (M = 0.30, SD = 2.39) than non-visitors (M = 0.34, SD = 2.07), P 
< 0.001, ER visits were lower among GP visitors (M = 0.32, SD = 1.20) than non-
visitors (M = 0.33, SD = 2.09), P < 0.001, and both were signiﬁ cantly higher among 
those with more prescriptions, ps < 0.001. The beneﬁ ts of a GP were largely indepen-
dent of number of medications. CONCLUSIONS: Among European patients taking 
prescriptions, visiting a GP was associated with greater adherence and lower health 
care resource utilization.
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OBJECTIVES: The aim of this study is to answer the following questions: 1) How 
high is the self-reported nonadherence (NA) of German patients with the need to regu-
larly take medication? and 2) Which factors capable of explaining this self-reported 
NA can be identiﬁ ed by multivariate analysis? METHODS: Two cross-sectional 
surveys (phone survey with 1177 patients; face-to-face in-depth survey with 340 
patients in 17 German pharmacies) were conducted. Self-reported NA was measured 
by the generic Morisky scale (either as 4 items or 8 item MMAS). Identiﬁ cation of 
explanatory factors was conducted on the basis of multivariate logistic regression 
analysis (including the calculation of additive risks by dichotomization of signiﬁ cant 
explanatory factors). RESULTS: 1) Approximately 35–40 % of the patients can be 
described as non-adherent (38.8 %/35.3 %); 2a) Survey 1: Only a few socio-demo-
graphic factors are able to explain the NA (chronic disease, some aspects of age, and 
low number of required medications to take); and 2b) Survey 2: Most results of the 
ﬁ rst survey can be replicated. However, intentional NA explanations have consider-
ably more inﬂ uence: positive medication belief, a positive mood, and a good patient-
doctor relationship reduce the NA risk. Furthermore, patients who are easily able to 
recognize the correct medication on the basis of the identiﬁ cation of the packaging 
have a signiﬁ cantly reduced NA probability. When additive risk is considered, patients 
who are chronically ill but display no other risk factors have an NA probability rate 
of 10.4 %, for patients displaying all identiﬁ ed risk factors this rate increases to 93.9 
%. CONCLUSIONS: Our surveys are the largest and most detailed to have been 
conducted in Germany concerned with the theme of medication-based NA. Our results 
show that approximately one-third of patients can be classiﬁ ed as non-adherent. 
Intentional NA factors explain the NA considerably better than do socio-economic 
factors.
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OBJECTIVES: A regional health plan implemented a specialty pharmacy beneﬁ t with 
increased copayment/coinsurance for specialty medications. Our objective was to 
measure and compare the change in adherence and persistence after implementation 
of the specialty beneﬁ t. METHODS: Pharmacy claims for patients who chronically 
used anti-inﬂ ammatory, immunosuppressant, cancer, and multiple sclerosis medica-
tions were assessed. The intervention group consisted of those whose out-of-pocket 
cost-share for specialty medications increased by at least $25 (per 30-day ﬁ ll), and the 
control group consisted of those whose out-of-pocket amounts did not change. Adher-
ence, deﬁ ned by proportion of days covered (PDC), was measured every 3 months for 
12 months before and after the copay change. Paired t-tests compared the adherence 
in the pre- vs. post-periods. Individual growth model analysis evaluated the changes 
in adherence throughout the time periods. Cox regression analysis determined the 
difference in persistence between groups after the copay change, controlling for age, 
gender, copay level, group, and pre-period persistence. RESULTS: There were 237 
patients in the intervention group and 211 patients in the control group. The PDC 
results varied by drug type; adherence decreased after the copay change in the interven-
tion group for patients on anti-inﬂ ammatory, immunosuppressant, and multiple scle-
rosis medications, but remained consistent for patients on antineoplastics. The growth 
model showed a small, but statistically signiﬁ cant decrease in PDC of 0.01 after copay 
changes (P = 0.014). The Cox regression analysis indicated that the estimated risk of 
discontinuing therapy increased for patients in the intervention vs. control groups 
(hazard ratio = 2.35, 95% CI: 1.43–3.58). CONCLUSIONS: The move to the specialty 
pharmacy beneﬁ t allows for closer scrutiny of specialty utilization by pharmacists who 
actively monitor utilization and access. Despite the minimal adherence decrease and 
signiﬁ cant persistence changes, the results indicated relatively more stability with the 
use of specialty medications than that reported with copayment/coinsurance increases 
for traditional pharmaceutics.
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OBJECTIVES: Women with PMO are most often treated with bisphosphonates (BPs), 
as well as with strontium ranelate (SR) and raloxifene (RLX). However, a high per-
centage of patients are not persistent after 1 year of therapy, which can compromise 
treatment effectiveness (Imaz I, Osteoporos Int 2010) and thus increase the risk of 
fractures. The objective was to estimate the persistence to PMO treatments in a region 
of Spain (Catalonia) representative of the Spanish population. METHODS: This 
database analysis included women with PMO from 6 primary care centers, aged ≥50 
years who initiated BPs (alendronate, ibandronate, risedronate), SR or RLX between 
January 1, 2004 and June 30, 2008. Patients with cancer, other bone diseases, hospi-
talization >30 days or <1 year follow-up data were excluded. Persistence was measured 
at 1, 2 or 3 years according to prescriptions dispensed at ofﬁ ce-based pharmacies. 
Three patients’ cohorts were analyzed: patients with ≥1 year (cohort 1), ≥2 years 
(cohort 2) and ≥3 years (cohort 3) follow-up. Patients with no access to medication 
for >1 month were considered non-persistent and a switch to another PMO treatment 
was considered a discontinuation. In a secondary analysis, switch was not considered 
a discontinuation. Statistics were performed using Kaplan-Meier methodology. 
RESULTS: A total of 3,049 patients (mean age ± SD; 68.3 ± 9.7 years) were included 
in cohort 1; 30% were persistent after 1 year (95%CI:27.5–32.5). In cohort 2 (n = 
2698; 68.9 ± 9.3 years) persistence was 35% (CI:32.6–36.2) and 16% (CI:13.6–19.2) 
after 1 and 2 years respectively. In cohort 3 (n = 2163; 68.4 ± 9.5 years) persistence 
was 36% (CI:33.9–37.9), 20% (CI:18.3–21.7) and 9% (CI:5.9–12.1) after 1, 2 and 
3 years, respectively. The results were similar by drug and frequency of administration, 
and also when switch was not considered a discontinuation. CONCLUSIONS: In this 
Spanish population of postmenopausal women with osteoporosis, persistence to treat-
ment was poor, even when a switch was not considered a discontinuation.
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OBJECTIVES: Our study focused on revealing difﬁ culties in maintaining balance 
during pregnancy. METHODS: Balance testing was performed on 150 volunteers (50 
healthy pregnant, 50 pathologically pregnant, 50 healthy young non—pregnant 
women). One hundred pregnant women were allocated into 4 subgroups based on 
physical activity performed prior to and during pregnancy. During stabilometer mea-
surements static balance was examined with Romberg test while dynamic balance with 
5 programs on a stabilometer. Statistical data were calculated according to mean, 
standard deviation and T-test while the results were considered to be relevant at P < 
0,05. RESULTS: Average results of Romberg test were worse in groups of pregnant 
women compared to non-pregnant women although the difference was not signiﬁ cant. 
Concerning the subgroups: those who had previously been involved in professional 
sports and were healthy and physically active during pregnancy performed better on 
the open–eye test (P < 0,05) compared to pathologically pregnant patients. Between 
the second and third trimesters of healthy pregnancies no signiﬁ cant results were found 
in Romberg test while a signiﬁ cant difference was detected (P < 0,05) in the perfor-
mance of the 5th exercise of the dynamic balance test. Regarding the 5 programs on 
the stabilometer examining dynamic balance non-pregnant women performed all 
exercises signiﬁ cantly better (P < 0,05) than healthy pregnant women. However when 
compared to pathologically pregnant women apart from the exercises No.2 the result 
showed a signiﬁ cant difference (P < 0,05). Concerning the same exercises healthy 
pregnant women performed signiﬁ cantly better (P < 0,05) in exercises No.1 and No.4. 
Pregnant women who had previously been and remained physically active during 
pregnancy performed the exercise of moving the centre of body weight in a signiﬁ -
cantly shorter time than those who were inactive and hospitalised. CONCLUSIONS: 
Statistical analysis of data proves that physical activity (especially professional sports) 
prior to becoming pregnant and physical activity during pregnancy have positive 
effects.
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OBJECTIVES: Treatments to prevent prostate cancer are associated with side effects 
and the impact of these on health related quality of life (HRQL) should be considered 
in any assessment of cost-effectiveness. However our systematic review identiﬁ ed a 
lack of robust data. a prospective assessment of the impact of side effects was under-
taken using generic and condition-speciﬁ c measures of HRQL. METHODS: Partici-
pants were recruited from an online panel. Men over 55, with either erectile 
dysfunction (ED), loss of libido, gynecomastia or ejaculatory disorders (without other 
chronic disease such as renal failure, diabetes, multiple sclerosis etc), and an age 
matched control group completed assessments of symptom severity and HRQL 
(EQ-5D and Sexual QoL survey—SQoL-3D). Both HRQL measures can provide 
